ProQR (PRQR) Investors: H.C. Wainwright Reiterates Buy Rating, Sees $40.0000/Share, Venor Capital Management LP Has Lifted Its Assured Guaranty LTD (AGO) Stake

June 20, 2017 - By Michael Collier

Among 3 analysts covering ProQR Therapeutics N.V. (NASDAQ:PRQR), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. ProQR Therapeutics N.V. has $14 highest and $4.50 lowest target. $9.25’s average target is 88.78% above currents $4.9 stock price. ProQR Therapeutics N.V. had 3 analyst reports since March 15, 2016 according to SRatingsIntel. The firm has “Neutral” rating by Janney Capital given on Thursday, September 29. Chardan Capital Markets initiated ProQR Therapeutics NV (NASDAQ:PRQR) rating on Monday, June 20. Chardan Capital Markets has “Neutral” rating and $4.50 target. The stock of ProQR Therapeutics NV (NASDAQ:PRQR) earned “Market Outperform” rating by JMP Securities on Tuesday, March 15.

Venor Capital Management Lp increased Assured Guaranty Ltd (AGO) stake by 23.59% reported in 2016Q4 SEC filing. Venor Capital Management Lp acquired 155,064 shares as Assured Guaranty Ltd (AGO)’s stock declined 5.68%. The Venor Capital Management Lp holds 812,529 shares with $30.69 million value, up from 657,465 last quarter. Assured Guaranty Ltd now has $5.11B valuation. The stock decreased 0.10% or $0.04 during the last trading session, reaching $41.94. About shares traded. Assured Guaranty Ltd. (NYSE:AGO) has risen 51.57% since June 20, 2016 and is uptrending. It has outperformed by 34.87% the S&P500.

Among 6 analysts covering Assured Guaranty (NYSE:AGO), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Assured Guaranty had 7 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of Assured Guaranty Ltd. (NYSE:AGO) earned “Mkt Perform” rating by Keefe Bruyette & Woods on Tuesday, February 28. The firm has “Buy” rating by M Partners given on Monday, November 16. The stock of Assured Guaranty Ltd. (NYSE:AGO) has “Buy” rating given on Friday, May 26 by BTIG Research. Macquarie Research maintained the shares of AGO in report on Monday, November 9 with “Outperform” rating. The rating was maintained by Wood on Friday, April 7 with “Hold”. On Tuesday, November 10 the stock rating was maintained by UBS with “Buy”. Zacks downgraded the stock to “Buy” rating in Wednesday, August 12 report.

Investors sentiment increased to 1.24 in Q4 2016. Its up 0.26, from 0.98 in 2016Q3. It increased, as 30 investors sold AGO shares while 84 reduced holdings. 50 funds opened positions while 91 raised stakes. 119.74 million shares or 2.02% less from 122.20 million shares in 2016Q3 were reported. Teacher Retirement Sys Of Texas stated it has 0% in Assured Guaranty Ltd. (NYSE:AGO). American Intl Grp Inc Inc has invested 0% of its portfolio in Assured Guaranty Ltd. (NYSE:AGO). Tower Cap Lc (Trc) reported 0.02% in Assured Guaranty Ltd. (NYSE:AGO). Natl Bank Of Hawaii reported 16,695 shares. Parkside Natl Bank Trust has 1,380 shares. Amp Cap Invsts Limited holds 0.01% in Assured Guaranty Ltd. (NYSE:AGO) or 50,384 shares. Brinker Incorporated holds 0.02% or 8,979 shares in its portfolio. California Employees Retirement System invested in 548,792 shares or 0.03% of the stock. Cap One Association owns 0.21% invested in Assured Guaranty Ltd. (NYSE:AGO) for 75,947 shares. Allianz Asset Ag invested in 63,160 shares. Thompson Siegel & Walmsley Limited holds 0.16% or 323,188 shares. Creative Planning reported 0% of its portfolio in Assured Guaranty Ltd. (NYSE:AGO). 32,700 are owned by Riverhead Capital Mngmt Lc. Blackrock Institutional Com Na reported 3.51 million shares or 0.02% of all its holdings. Timber Hill Limited Liability Co has 0% invested in Assured Guaranty Ltd. (NYSE:AGO).

Since May 10, 2017, it had 0 insider purchases, and 1 sale for $470,280 activity. 12,000 shares were sold by Albert Howard, worth $470,280 on Wednesday, May 10.

ProQR Therapeutics N.V. , formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The company has market cap of $114.95 million. The Firm is engaged in the discovery and development of ribonucleic Acid (RNA) therapeutics for the treatment of severe genetic disorders. It currently has negative earnings. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

The stock decreased 1.01% or $0.05 on June 19, reaching $4.9. About shares traded. ProQR Therapeutics NV (NASDAQ:PRQR) has risen 37.60% since June 20, 2016 and is uptrending. It has outperformed by 20.90% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: